Cargando…
A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients
BACKGROUND: Tenofovir disoproxil fumarate (TDF, Viread(®)) had been used as a standard treatment option of chronic hepatitis B (CHB). This clinical trial was conducted to evaluate the efficacy and safety of DA-2802 (tenofovir disoproxil orotate) compared to TDF. METHODS: The present study was a doub...
Autores principales: | Kim, Hyung Joon, Kim, Ju Hyun, Yeon, Jong Eun, Seo, Yeon Seok, Jang, Jeong Won, Cho, Yong Kyun, Jang, Byoung Kuk, Han, Byung Hoon, Lee, Changhyeong, Lee, Joon Hyeok, Yoon, Jung-Hwan, Kim, Kang Mo, Kim, Moon Young, Kim, Do Young, Park, Neung Hwa, Cho, Eun Young, Lee, June Sung, Lee, Jin-Woo, Kim, In Hee, Song, Byung-Cheol, Lee, Byung-Seok, Kwon, Oh Sang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938614/ https://www.ncbi.nlm.nih.gov/pubmed/35315603 http://dx.doi.org/10.3346/jkms.2022.37.e92 |
Ejemplares similares
-
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022) -
Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study
por: Chang, Young, et al.
Publicado: (2021) -
Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021) -
Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice
por: Song, Jeong Eun, et al.
Publicado: (2019) -
Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients
por: Lee, Heon Ju, et al.
Publicado: (2018)